Trecondi
What Trecondi is used for
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Trecondi
- Active substance
- treosulfan
- Disease area
- Hematopoietic Stem Cell Transplantation
- Medicine group
- Antineoplastic agents
- ATC code
- L01AB02
- Marketing authorisation holder
- medac Gesellschaft für klinische Spezialpräparate mbH
- Authorised in the EU since
- 2019
Official information
In India
- Treosulfan: 1 brand in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Trecondi used for?
Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases.
What is the active substance in Trecondi?
Trecondi contains treosulfan.
Who makes Trecondi?
The EU marketing authorisation holder is medac Gesellschaft für klinische Spezialpräparate mbH.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU